anlotinib + tislelizumab + irinotecan

A combination therapy consisting of anlotinib (a multi-target tyrosine kinase inhibitor with anti-angiogenic properties), tislelizumab (an anti-PD-1 monoclonal antibody), and irinotecan (a topoisomerase I inhibitor chemotherapy agent). This regimen is being investigated primarily as a second-line treatment for extensive-stage small cell lung cancer (ES-SCLC) after progression on platinum-based chemotherapy. The combination works through multiple complementary mechanisms: - **Tislelizumab** targets PD-1, blocking the interaction between PD-1 and its ligands to restore anti-tumor immune responses. - **Anlotinib** inhibits vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and other kinases involved in tumor angiogenesis. - **Irinotecan** is a topoisomerase I inhibitor chemotherapy agent that prevents DNA replication in cancer cells. A phase II trial (NCT05027100) in ES-SCLC evaluated this combination. The treatment protocol typically involves tislelizumab (200 mg IV every 3 weeks), anlotinib (10 mg orally, days 1-14 of a 21-day cycle), and irinotecan (100 mg/m² IV, days 1 and 8) for two 21-day cycles, followed by maintenance with tislelizumab and anlotinib.